p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma

Yuan-Deng Luo,Lei Fang,Hong-Qiang Yu,Jie Zhang,Xiao-Tong Lin,Xiao-Yu Liu,Di Wu,Gui-Xi Li,Deng Huang,Yu-Jun Zhang,Shu Chen,Yan Jiang,Ling Shuai,Yu He,Lei-Da Zhang,Ping Bie,Chuan-Ming Xie
DOI: https://doi.org/10.1016/j.jhep.2020.07.036
IF: 25.7
2021-01-01
Journal of Hepatology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and Aims</h3><p>p53 mutations occur frequently in human hepatocellular carcinoma (HCC). Activation of the mammalian target of rapamycin (mTOR) pathway is also associated with HCC. However, it is still unknown whether these changes together initiate HCC and can be targeted as a potential therapeutic strategy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We generated mouse models in which mTOR was hyperactivated by loss of tuberous sclerosis complex 1 (Tsc1) with or without p53 haplodeficiency. Primary cells were isolated from mouse livers. Oncogenic signaling was assessed <em>in vitro</em> and <em>in vivo</em>, with or without targeted inhibition of a single molecule or multiple molecules. Transcriptional profiling was used to identify biomarkers predictive of HCC. Human HCC materials were used to corroborate the findings from mouse models.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>p53 haploinsufficiency facilitates mTOR signaling via the Pten/PI3k/Akt axis, promoting HCC tumorigenesis and lung metastasis. Inhibition of PI3K/Akt reduced mTOR activity, which effectively enhanced the anticancer effort of an mTOR inhibitor. Abcc4 was found to be responsible for p53 haploinsufficiency- and Tsc1 loss-driven HCC tumorigenesis. Moreover, in clinical HCC samples, Abcc4 specifically identified an aggressive subtype. The mTOR inhibitor rapamycin significantly reduced hepatocarcinogenesis triggered by Tsc1 loss and p53 haploinsufficiency <em>in vivo</em>, as well as the biomarker Abcc4.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Our data advance the current understanding of the activation of the Pten/PI3K/Akt/mTOR axis and its downstream target Abcc4 in hepatocarcinogenesis driven by p53 reduction and Tsc1 loss. Targeting mTOR, an unexpected vulnerability in p53 (haplo)deficiency HCC, can be exploited therapeutically to treat Abcc-4-positive HCC patients.</p>
gastroenterology & hepatology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the roles of p53 haploinsufficiency and enhanced mTOR signaling pathway in the occurrence and development of hepatocellular carcinoma (HCC), especially whether they jointly promote the development of a more aggressive HCC subtype. Specifically, the researchers want to understand: 1. **How does p53 haploinsufficiency promote the activation of the mTOR signaling pathway**: By studying the influence of p53 haploinsufficiency on the mTOR signaling pathway and how this influence promotes the occurrence and development of HCC. 2. **Characteristics of HCC under the combined action of p53 haploinsufficiency and Tsc1 deletion**: Study the molecular mechanism of HCC under the combined action of p53 haploinsufficiency and Tsc1 deletion, especially whether these changes will lead to a more aggressive HCC subtype. 3. **Potential treatment strategies**: Explore whether inhibitors targeting the mTOR signaling pathway can be an effective means to treat this aggressive HCC subtype. The paper systematically studied these problems by generating mouse models with specific gene knock - out, combining in vitro and in vivo experiments, and analyzing clinical samples. The main findings include: - p53 haploinsufficiency further activates the mTOR signaling pathway through the Pten/PI3K/Akt axis, thereby promoting the occurrence and development of HCC. - Under the combined action of Tsc1 deletion and p53 haploinsufficiency, the invasiveness and metastatic ability of HCC are significantly enhanced. - Inhibiting the mTOR signaling pathway can effectively reduce the occurrence and development of HCC caused by p53 haploinsufficiency and Tsc1 deletion. - Abcc4 has been identified as an important biomarker, which is related to HCC driven by p53 haploinsufficiency and Tsc1 deletion, and is clinically related to the poor prognosis of HCC patients. These findings provide a new perspective for understanding the roles of p53 haploinsufficiency and the mTOR signaling pathway in HCC, and provide a theoretical basis for developing treatment strategies for this aggressive HCC subtype.